Vor Historical Balance Sheet

VOR Stock

USD 0.83 0.04 5.06%

Trend analysis of Vor Biopharma balance sheet accounts such as Total Assets of 151.6 M, Short Long Term Debt Total of 25.4 M, Other Current Liabilities of 4.8 M or Total Current Liabilities of 10.8 M provides information on Vor Biopharma's total assets, liabilities, and equity, which is the actual value of Vor Biopharma to its prevalent stockholders. By breaking down trends over time using Vor Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vor Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vor Biopharma is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

About Vor Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vor Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Vor Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vor Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vor currently owns. An asset can also be divided into two categories, current and non-current.

Vor Biopharma Balance Sheet Chart

At this time, Vor Biopharma's Net Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Net Debt is likely to grow to about 4.5 M, while Short and Long Term Debt Total is likely to drop slightly above 25.4 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Retained Earnings Capital Surpluse

Add Fundamental

Total Assets

Total assets refers to the total amount of Vor Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vor Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Vor Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vor Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most accounts from Vor Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.At this time, Vor Biopharma's Net Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Net Debt is likely to grow to about 4.5 M, while Short and Long Term Debt Total is likely to drop slightly above 25.4 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	18.0M	38.9M	35.7M	25.4M
Total Assets	242.6M	299.4M	198.1M	151.6M

Short Long Term Debt Total Total Assets

Vor Biopharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.89	0.81	0.76	1.0	0.88	0.93	0.8	-0.58	-0.82	0.75	0.85	0.93	1.0	0.78	0.93	0.97	0.91	0.92	0.94	0.92	-0.37	1.0	-0.01	0.99	0.45
Short Long Term Debt Total	0.89		0.83	0.68	0.87	0.82	0.96	0.9	-0.28	-0.88	0.75	0.62	0.96	0.85	0.93	0.96	0.86	0.87	0.92	0.76	0.96	-0.5	0.85	0.15	0.85	0.41
Other Current Liab	0.81	0.83		0.84	0.78	0.71	0.88	0.83	-0.43	-0.83	0.82	0.72	0.9	0.77	0.88	0.91	0.8	0.77	0.92	0.6	0.87	-0.5	0.77	0.39	0.76	0.32
Total Current Liabilities	0.76	0.68	0.84		0.72	0.75	0.85	0.48	-0.18	-0.79	0.49	0.51	0.85	0.72	0.6	0.85	0.77	0.77	0.9	0.68	0.86	-0.46	0.72	-0.01	0.7	0.73
Total Stockholder Equity	1.0	0.87	0.78	0.72		0.88	0.9	0.79	-0.61	-0.8	0.75	0.87	0.91	1.0	0.76	0.91	0.97	0.9	0.89	0.95	0.9	-0.35	1.0	-0.03	1.0	0.42
Net Tangible Assets	0.88	0.82	0.71	0.75	0.88		0.84	0.66	-0.3	-0.94	0.5	0.67	0.84	0.87	0.75	0.83	0.93	0.99	0.83	0.89	0.85	-0.7	0.87	-0.3	0.87	0.65
Property Plant And Equipment Net	0.93	0.96	0.88	0.85	0.9	0.84		0.8	-0.3	-0.89	0.73	0.65	1.0	0.89	0.85	1.0	0.9	0.89	0.99	0.82	1.0	-0.45	0.89	0.1	0.88	0.55
Current Deferred Revenue	0.8	0.9	0.83	0.48	0.79	0.66	0.8		-0.52	-0.73	0.85	0.73	0.83	0.77	0.96	0.83	0.77	0.72	0.77	0.61	0.8	-0.38	0.77	0.39	0.77	0.04
Net Debt	-0.58	-0.28	-0.43	-0.18	-0.61	-0.3	-0.3	-0.52		0.15	-0.6	-0.89	-0.33	-0.63	-0.36	-0.34	-0.55	-0.31	-0.32	-0.52	-0.28	-0.17	-0.63	-0.22	-0.64	0.27
Retained Earnings	-0.82	-0.88	-0.83	-0.79	-0.8	-0.94	-0.89	-0.73	0.15		-0.58	-0.57	-0.89	-0.78	-0.85	-0.88	-0.85	-0.96	-0.88	-0.74	-0.9	0.8	-0.78	0.07	-0.77	-0.61
Accounts Payable	0.75	0.75	0.82	0.49	0.75	0.5	0.73	0.85	-0.6	-0.58		0.81	0.76	0.74	0.75	0.78	0.63	0.59	0.74	0.5	0.71	-0.27	0.74	0.62	0.74	-0.13
Cash	0.85	0.62	0.72	0.51	0.87	0.67	0.65	0.73	-0.89	-0.57	0.81		0.68	0.88	0.64	0.69	0.81	0.69	0.67	0.75	0.64	-0.24	0.88	0.19	0.88	0.03
Non Current Assets Total	0.93	0.96	0.9	0.85	0.91	0.84	1.0	0.83	-0.33	-0.89	0.76	0.68		0.9	0.87	1.0	0.91	0.9	0.99	0.81	1.0	-0.46	0.9	0.12	0.89	0.53
Cash And Short Term Investments	1.0	0.85	0.77	0.72	1.0	0.87	0.89	0.77	-0.63	-0.78	0.74	0.88	0.9		0.75	0.9	0.97	0.9	0.88	0.95	0.89	-0.34	1.0	-0.04	1.0	0.42
Common Stock Shares Outstanding	0.78	0.93	0.88	0.6	0.76	0.75	0.85	0.96	-0.36	-0.85	0.75	0.64	0.87	0.75		0.86	0.8	0.8	0.83	0.62	0.85	-0.55	0.75	0.27	0.74	0.24
Non Current Liabilities Total	0.93	0.96	0.91	0.85	0.91	0.83	1.0	0.83	-0.34	-0.88	0.78	0.69	1.0	0.9	0.86		0.89	0.88	0.99	0.8	0.99	-0.45	0.89	0.17	0.89	0.5
Other Current Assets	0.97	0.86	0.8	0.77	0.97	0.93	0.9	0.77	-0.55	-0.85	0.63	0.81	0.91	0.97	0.8	0.89		0.93	0.89	0.95	0.9	-0.43	0.97	-0.14	0.97	0.54
Other Stockholder Equity	0.91	0.87	0.77	0.77	0.9	0.99	0.89	0.72	-0.31	-0.96	0.59	0.69	0.9	0.9	0.8	0.88	0.93		0.88	0.88	0.9	-0.7	0.89	-0.19	0.89	0.62
Total Liab	0.92	0.92	0.92	0.9	0.89	0.83	0.99	0.77	-0.32	-0.88	0.74	0.67	0.99	0.88	0.83	0.99	0.89	0.88		0.79	0.99	-0.46	0.88	0.13	0.87	0.56
Net Invested Capital	0.94	0.76	0.6	0.68	0.95	0.89	0.82	0.61	-0.52	-0.74	0.5	0.75	0.81	0.95	0.62	0.8	0.95	0.88	0.79		0.82	-0.31	0.95	-0.34	0.95	0.59
Property Plant And Equipment Gross	0.92	0.96	0.87	0.86	0.9	0.85	1.0	0.8	-0.28	-0.9	0.71	0.64	1.0	0.89	0.85	0.99	0.9	0.9	0.99	0.82		-0.47	0.89	0.07	0.88	0.58
Short Long Term Debt	-0.37	-0.5	-0.5	-0.46	-0.35	-0.7	-0.45	-0.38	-0.17	0.8	-0.27	-0.24	-0.46	-0.34	-0.55	-0.45	-0.43	-0.7	-0.46	-0.31	-0.47		-0.34	0.12	-0.33	-0.42
Total Current Assets	1.0	0.85	0.77	0.72	1.0	0.87	0.89	0.77	-0.63	-0.78	0.74	0.88	0.9	1.0	0.75	0.89	0.97	0.89	0.88	0.95	0.89	-0.34		-0.04	1.0	0.42
Capital Stock	-0.01	0.15	0.39	-0.01	-0.03	-0.3	0.1	0.39	-0.22	0.07	0.62	0.19	0.12	-0.04	0.27	0.17	-0.14	-0.19	0.13	-0.34	0.07	0.12	-0.04		-0.04	-0.62
Net Working Capital	0.99	0.85	0.76	0.7	1.0	0.87	0.88	0.77	-0.64	-0.77	0.74	0.88	0.89	1.0	0.74	0.89	0.97	0.89	0.87	0.95	0.88	-0.33	1.0	-0.04		0.4
Short Term Debt	0.45	0.41	0.32	0.73	0.42	0.65	0.55	0.04	0.27	-0.61	-0.13	0.03	0.53	0.42	0.24	0.5	0.54	0.62	0.56	0.59	0.58	-0.42	0.42	-0.62	0.4

Click cells to compare fundamentals

Vor Biopharma Account Relationship Matchups

Vor Biopharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.8M	75.9M	242.6M	299.4M	198.1M	151.6M
Other Current Liab	1.5M	6.1M	4.9M	4.8M	7.1M	4.8M
Total Current Liabilities	2.2M	10.2M	10.2M	13.1M	15.6M	10.8M
Total Stockholder Equity	7.6M	48.3M	216.3M	250.6M	150.7M	122.2M
Net Tangible Assets	(17.4M)	(59.1M)	216.3M	250.6M	288.2M	302.6M
Property Plant And Equipment Net	728K	21.8M	22.5M	57.1M	50.1M	27.9M
Net Debt	(6.5M)	(30.2M)	(101.8M)	(18.8M)	4.3M	4.5M
Retained Earnings	(17.9M)	(61.2M)	(130.1M)	(222.2M)	(340.1M)	(323.1M)
Accounts Payable	693K	2.4M	1.5M	1.8M	815K	1.3M
Cash	6.5M	48.5M	119.8M	57.7M	31.4M	48.5M
Non Current Assets Total	2.3M	26.8M	28.2M	62.4M	57.3M	32.5M
Cash And Short Term Investments	6.5M	48.5M	207.5M	230.2M	137.2M	115.7M
Common Stock Shares Outstanding	37.1M	37.1M	37.2M	39.6M	67.2M	41.0M
Liabilities And Stockholders Equity	9.8M	75.9M	242.6M	299.4M	198.1M	151.6M
Non Current Liabilities Total	693K	17.4M	16.2M	35.6M	31.8M	18.7M
Other Current Assets	205K	567K	6.9M	6.7M	6.8M	3.9M
Other Stockholder Equity	458K	2.2M	346.4M	473.6M	490.9M	515.4M
Total Liab	2.2M	27.6M	26.3M	48.8M	47.4M	29.3M
Net Invested Capital	(17.4M)	(59.1M)	216.3M	250.6M	150.7M	98.8M
Property Plant And Equipment Gross	728K	21.8M	24.6M	61.7M	58.2M	30.6M
Total Current Assets	7.5M	49.1M	214.4M	237.0M	140.8M	119.1M
Capital Stock	25.1M	107.3M	4K	7K	6.3K	6.0K
Net Working Capital	5.4M	38.9M	204.2M	223.8M	125.2M	108.3M
Property Plant Equipment	728K	21.8M	6.9M	12.6M	14.5M	9.3M

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Vor Stock

0.78	HCM	HUTCHMED DRC	Pair Corr
0.65	BCTXW	BriaCell Therapeutics	Pair Corr
0.51	GANX	Gain Therapeutics	Pair Corr
0.48	EWTX	Edgewise Therapeutics	Pair Corr
0.36	BHC	Bausch Health Companies	Pair Corr

The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.

The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vor Historical Balance Sheet

About Vor Balance Sheet Analysis

Vor Biopharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Retained Earnings

Vor Biopharma balance sheet Correlations

Vor Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vor Biopharma balance sheet Accounts

Pair Trading with Vor Biopharma

Moving against Vor Stock

Additional Tools for Vor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.96	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Property Plant And Equipment Gross	- 0.9	Retained Earnings
Non Current Assets Total	- 0.89	Retained Earnings
Cash	- 0.89	Net Debt
Retained Earnings	- 0.89	Property Plant And Equipment Net